bioGenous offers pharmaceutical companies an opportunity to screen and develop new drugs using highly innovative technology. Organoids are highly consistent with their source tissues in terms of tissue structure, cell types, self-renewal ability, and function. The novel organoid technology and drug screening platform provided by bioGenous allows manufacturers to obtain direct effects of new drugs on human organs, which can shorten the drug development process and accelerate the launch of new drugs and therapies.
